Status: Recruiting
CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases
CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases
Participants needed: 12
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Institute of Hematology & Blood Diseases Hospital, ChinaUpdated: Jan 20, 2026Locations: 1
Eligibility criteria
Age ≥ 18 years old (inclusive), regardless of gender. [+23]
Subjects with a history of severe drug allergies or allergic tendencies. [+12]